This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marcos, N. T. Articles by Reis, C. A. Search for Related Content PubMed PubMed Citation Articles by Marcos, N. T. Articles by Reis, C. A.

Role of the Human ST6GalNAc-I and ST6GalNAc-II in the Synthesis of the Cancer-Associated Sialyl-Tn Antigen

¹ Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal; ² Unité de Glycobiologie Structurale et Fonctionnelle, Unité Mixte de Recherche Centre National de la Recherche Scientifique 8576, Université de Science et Technologies de Lille, Villeneuve d’Ascq, France; ³ Laboratory of Glycobiology, Instituto de Tecnologia Química e Biológica, Oeiras, Portugal; ⁴ Organic Chemistry, Department of Chemistry, Umea University, Umea, Sweden; and ⁵ Department of Oral Diagnostics, School of Dentistry, Copenhagen, Denmark

The Sialyl-Tn antigen (Neu5Ac2–6GalNAc-O-Ser/Thr) is highly expressed in several human carcinomas and is associated with carcinoma aggressiveness and poor prognosis. We characterized two human sialyltransferases, CMP-Neu5Ac:GalNAc-R 2,6-sialyltransferase (ST6GalNAc)-I and ST6GalNAc-II, that are candidate enzymes for Sialyl-Tn synthases. We expressed soluble recombinant hST6GalNAc-I and hST6GalNAc-II and characterized the substrate specificity of both enzymes toward a panel of glycopeptides, glycoproteins, and other synthetic glycoconjugates. The recombinant ST6GalNAc-I and ST6GalNAc-II showed similar substrate specificity toward glycoproteins and GalNAc-O-Ser/Thr glycopeptides, such as glycopeptides derived from the MUC2 mucin and the HIVgp120. We also observed that the amino acid sequence of the acceptor glycopeptide contributes to the in vitro substrate specificity of both enzymes. We additionally established a gastric cell line, MKN45, stably transfected with the full length of either ST6GalNAc-I or ST6GalNAc-II and evaluated the carbohydrate antigens expression profile induced by each enzyme. MKN45 transfected with ST6GalNAc-I showed high expression of Sialyl-Tn, whereas MKN45 transfected with ST6GalNAc-II showed the biosynthesis of the Sialyl-6T structure [Galß1–3 (Neu5Ac2–6)GalNAc-O-Ser/Thr].

In conclusion, although both enzymes show similar in vitro activities when Tn antigen alone is available, whenever both Tn and T antigens are present, ST6GalNAc-I acts preferentially on Tn antigen, whereas the ST6GalNAc-II acts preferentially on T antigen. Our results show that ST6GalNAc-I is the major Sialyl-Tn synthase and strongly support the hypothesis that the expression of the Sialyl-Tn antigen in cancer cells is due to ST6GalNAc-I activity.

This article has been cited by other articles:

				T. Angata, Y. Tabuchi, K. Nakamura, and M. Nakamura Siglec-15: an immune system Siglec conserved throughout vertebrate evolution Glycobiology, August 1, 2007; 17(8): 838 - 846. [Abstract] [Full Text] [PDF]

				K. Kato, C. Jeanneau, M. A. Tarp, A. Benet-Pages, B. Lorenz-Depiereux, E. P. Bennett, U. Mandel, T. M. Strom, and H. Clausen Polypeptide GalNAc-transferase T3 and Familial Tumoral Calcinosis: SECRETION OF FIBROBLAST GROWTH FACTOR 23 REQUIRES O-GLYCOSYLATION J. Biol. Chem., July 7, 2006; 281(27): 18370 - 18377. [Abstract] [Full Text] [PDF]

				N. Berois, D. Mazal, L. Ubillos, F. Trajtenberg, A. Nicolas, X. Sastre-Garau, H. Magdelenat, and E. Osinaga UDP-N-Acetyl-D-Galactosamine: Polypeptide N-Acetylgalactosaminyltransferase-6 as a New Immunohistochemical Breast Cancer Marker J. Histochem. Cytochem., March 1, 2006; 54(3): 317 - 328. [Abstract] [Full Text] [PDF]

				R. Sewell, M. Backstrom, M. Dalziel, S. Gschmeissner, H. Karlsson, T. Noll, J. Gatgens, H. Clausen, G. C. Hansson, J. Burchell, et al. The ST6GalNAc-I Sialyltransferase Localizes throughout the Golgi and Is Responsible for the Synthesis of the Tumor-associated Sialyl-Tn O-Glycan in Human Breast Cancer J. Biol. Chem., February 10, 2006; 281(6): 3586 - 3594. [Abstract] [Full Text] [PDF]

				A. L. Sorensen, C. A. Reis, M. A. Tarp, U. Mandel, K. Ramachandran, V. Sankaranarayanan, T. Schwientek, R. Graham, J. Taylor-Papadimitriou, M. A. Hollingsworth, et al. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance Glycobiology, February 1, 2006; 16(2): 96 - 107. [Abstract] [Full Text] [PDF]

				S. Julien, E. Adriaenssens, K. Ottenberg, A. Furlan, G. Courtand, A.-S. Vercoutter-Edouart, F.-G. Hanisch, P. Delannoy, and X. Le Bourhis ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity Glycobiology, January 1, 2006; 16(1): 54 - 64. [Abstract] [Full Text] [PDF]

				A. Harduin-Lepers, R. Mollicone, P. Delannoy, and R. Oriol The animal sialyltransferases and sialyltransferase-related genes: a phylogenetic approach Glycobiology, August 1, 2005; 15(8): 805 - 817. [Abstract] [Full Text] [PDF]